

Remarks

Claims 15-26 were pending in the subject application. By this Amendment, claims 15, 23, and 25 have been amended and claims 20-22, 24, and 26 have been cancelled. The undersigned avers that no new matter is introduced by this amendment. Entry and consideration of the amendments presented herein is respectfully requested. Accordingly, claims 15-19, 23, and 25 are currently before the Examiner for consideration. Favorable consideration of the pending claims is respectfully requested.

The applicants and the applicants' representative wish to thank Examiners Haddad and Nolan for the courtesy of the telephonic interview conducted with the undersigned on August 10, 2004, regarding claim 15 and the rejection under 35 U.S.C. §112, first paragraph. The Amendment under 37 C.F.R. §1.111 and Declaration under 37 C.F.R. §1.132 by Dr. Nasser Chegini were discussed during the interview. The remarks and amendments set forth herein are consistent with the substance of the interview and are believed to address the outstanding issues as discussed during the interview.

An Amendment in response to the Office Action dated March 23, 2004 was submitted on July 23, 2004; the applicants presume that the Amendment has been entered. By this supplemental Amendment, claims 15, 23, and 25 have been amended. Support for the amendments to claim 15 can be found, for example, at page 3, lines 11-18, which indicate that formulations containing TIMP-1 antibodies can be used to reduce or prevent surgical adhesions; and page 3, lines 18-19, which indicates that treatment with TIMP-1 antibodies results in the alteration of local levels of TIMP-1 and MMP. Support for the amendments to claims 23 and 25 can be found, for example, at page 3, lines 11-18, which indicate that formulations containing TIMP-1 antibodies can be used to reduce or prevent surgical adhesions.

The applicants have amended the "Priority Claim" section at page 1 of the subject specification to indicate that the filing date of the international application is October 1, 1999, not October 10, 1999.

6


Docket No. UF-T397XC1
Serial No. 09/787,144

In view of the foregoing remarks and amendments to the claims, the applicants believe that the currently pending claims are in condition for allowance, and such action is respectfully requested.

The Commissioner is hereby authorized to charge any fees under 37 C.F.R. §§ 1.16 or 1.17 as required by this paper to Deposit Account 19-0065.

The applicants invite the Examiner to call the undersigned if clarification is needed on any of this response, or if the Examiner believes a telephonic interview would expedite the prosecution of the subject application to completion.

Respectfully submitted,



Glenn P. Ladwig
Patent Attorney
Registration No. 46,853
Phone No.: 352-375-8100
Fax No.: 352-372-5800
Address: Saliwanchik, Lloyd & Saliwanchik
A Professional Association
2421 NW 41st Street, Suite A-1
Gainesville, FL 32606-6669

GPL/mv